Key result
Left ventricular assist device support in end-stage heart failure patients was associated with significantly reduced myocardial MMP-2 and MMP-9 activities compared to medical therapy alone.
Why the study?
Does left ventricular assist device support alter myocardial redox state and matrix metalloproteinase activity in patients with end-stage heart failure?
Observational (n=14)
No
Does left ventricular assist device support alter myocardial redox state and matrix metalloproteinase activity in patients with end-stage heart failure?
Prolonged LVAD support in end-stage heart failure is associated with reduced myocardial MMP-2 and -9 activities and an altered redox state with higher GSH levels, which may inhibit MMP activity and modulate extracellular matrix remodeling.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for LVAD effects on matrix remodeling; does not support practice change without prospective trials.
BACKGROUND: Redox aminothiols have been reported to modulate the activity of recombinant metalloproteinases (MMP). The aim of the present study was to investigate the effects of myocardial redox state on the activities of MMP-2 and -9 implicated in cardiac remodeling in end-stage heart failure patients supported by left ventricular assist device (LVAD). METHODS AND RESULTS: During heart transplant (HT) surgery, myocardial specimens (MS) from right ventricular walls and LV walls were obtained from 7 LVAD recipients (LVAD group, MS n=35) and from 7 stable HT candidates on medical therapy (MT group, MS n=35). Myocardial MMP-2 and -9 activities and expression, tissue inhibitor of MMP (TIMP)-1 and -4, transforming growth factor (TGF)-β1 and aminothiol concentrations were measured. MMP-2 and -9 activities were evaluated also by incubating MS with different amounts of reduced and oxidized glutathione (GSH). MMP-2 and -9 activities and expression were lower in the LVAD group, whereas myocardial TIMP-1 and -4 concentrations were comparable to those of MT patients. Higher GSH and TGF-β1 concentrations were found in LVAD-recipients. Only GSH concentrations were inversely related to MMP-2 and -9 activities. In vitro, GSH had an inhibitory effect on MMP-2 and -9 activities. CONCLUSIONS: LVAD recipients show reduced myocardial MMP-2 and -9 activities and expression when compared to medically treated patients. Changes of myocardial redox state, predominantly GSH-dependent, appear to modulate MMP-2 and -9 activities by an inhibitory effect dependent on thiol content. These data support a role of GSH cycle in modulating the extracellular matrix in end-stage heart failure patients supported by LVAD.
No takes yet. Share an insight, caveat, or question.
Caruso et al. (2011) conducted an observational in End-stage heart failure (n=14). Left ventricular assist device (LVAD) vs. Medical therapy was evaluated on Myocardial MMP-2 activity (Arbitrary Units) (p=<0.001). Left ventricular assist device support in end-stage heart failure patients was associated with significantly reduced myocardial MMP-2 and MMP-9 activities compared to medical therapy alone.
Synapse has enriched 10 related papers. Consider them for comparative context: